Prof Meletios Dimopoulos speaks to ecancer about optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting.

He talks about the background of the use of BCMA-targeting agents in multiple myeloma and how we can optimise benefit-risk with these agents.

The risk versus benefit of BCMA-targeting agents is favourable because it is associated with a clinically meaningful elongation of progression-free survival of patients.